571.73
0.98%
-5.66
Pre-market:
571.73
Overview
News
Price History
Option Chain
Why TMO Down?
Discussions
Forecast
Stock Split
Dividend History
Thermo Fisher Scientific Inc. stock is currently priced at $571.73, with a 24-hour trading volume of 1.17M.
It has seen a -0.98% decreased in the last 24 hours and a -0.32% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $576.4 pivot point. If it approaches the $566.3 support level, significant changes may occur.
Previous Close:
$577.39
Open:
$577.4
24h Volume:
1.17M
Market Cap:
$218.24B
Revenue:
$42.86B
Net Income/Loss:
$6.00B
P/E Ratio:
37.47
EPS:
15.26
Net Cash Flow:
$6.93B
1W Performance:
+5.58%
1M Performance:
-0.32%
6M Performance:
+31.98%
1Y Performance:
+4.26%
Thermo Fisher Scientific Inc. Stock (TMO) Company Profile
Name
Thermo Fisher Scientific Inc.
Sector
Industry
Phone
781-622-1000
Address
168 Third Avenue, Waltham, MA
Thermo Fisher Scientific Inc. Stock (TMO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jan-24-24 | Downgrade | Barclays | Overweight → Equal Weight |
Jan-08-24 | Downgrade | Bernstein | Outperform → Mkt Perform |
Dec-18-23 | Initiated | HSBC Securities | Buy |
Dec-13-23 | Initiated | Wolfe Research | Outperform |
Oct-26-23 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Oct-25-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
Sep-28-23 | Initiated | Bernstein | Outperform |
Sep-06-23 | Resumed | Citigroup | Buy |
Jul-19-23 | Initiated | Raymond James | Outperform |
Jul-19-23 | Reiterated | Robert W. Baird | Outperform |
Jul-13-23 | Upgrade | Credit Suisse | Neutral → Outperform |
Apr-04-23 | Reiterated | Barclays | Overweight |
Dec-14-22 | Initiated | Deutsche Bank | Buy |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Oct-27-22 | Downgrade | The Benchmark Company | Buy → Hold |
Aug-25-22 | Initiated | Credit Suisse | Neutral |
Apr-25-22 | Downgrade | Wells Fargo | Equal Weight → Underweight |
Jan-26-22 | Resumed | Barclays | Overweight |
Oct-20-21 | Upgrade | Citigroup | Neutral → Buy |
Oct-15-21 | Resumed | Cowen | Outperform |
Aug-05-21 | Resumed | Credit Suisse | Outperform |
Jul-16-21 | Initiated | The Benchmark Company | Buy |
Mar-18-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
Mar-03-21 | Initiated | Barclays | Overweight |
Jan-08-21 | Upgrade | Credit Suisse | Neutral → Outperform |
Dec-16-20 | Downgrade | Citigroup | Buy → Neutral |
Dec-02-20 | Initiated | Goldman | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Sector Weight |
Sep-30-20 | Initiated | Atlantic Equities | Overweight |
Sep-14-20 | Initiated | Morgan Stanley | Overweight |
Aug-20-20 | Resumed | JP Morgan | Overweight |
Jul-15-20 | Upgrade | Cleveland Research | Neutral → Buy |
Jul-07-20 | Reiterated | Needham | Buy |
Apr-23-20 | Reiterated | Needham | Buy |
Jan-31-20 | Reiterated | Needham | Buy |
Jan-22-20 | Initiated | Credit Suisse | Neutral |
Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
Jan-07-20 | Initiated | Citigroup | Buy |
Nov-15-19 | Initiated | Stifel | Buy |
Jul-25-19 | Reiterated | Needham | Buy |
Jul-16-19 | Downgrade | Needham | Strong Buy → Buy |
May-30-19 | Initiated | Wolfe Research | Outperform |
May-23-19 | Reiterated | Needham | Strong Buy |
Apr-22-19 | Reiterated | Needham | Strong Buy |
Apr-16-19 | Reiterated | BofA/Merrill | Buy |
View All
Thermo Fisher Scientific Inc. Stock (TMO) Latest News
Company News for Apr 25, 2024
Zacks Investment Research
These Analysts Revise Their Forecasts On Thermo Fisher Scientific Following Upbeat Earnings
Benzinga
7 Analysts Assess Thermo Fisher Scientific: What You Need To Know
Benzinga
Thermo Fisher Scientific (TMO) Q1 2024 Earnings Call Transcript
The Motley Fool
Thermo Fisher (TMO) Q1 Earnings Top Estimates, 2024 View Up
Zacks Investment Research
Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What's Driving Markets Wednesday?
Benzinga
Thermo Fisher Scientific Inc. Stock (TMO) Financials Data
Thermo Fisher Scientific Inc. (TMO) Revenue 2024
TMO reported a revenue (TTM) of $42.86 billion for the quarter ending December 31, 2023, a -4.58% decline year-over-year.
Thermo Fisher Scientific Inc. (TMO) Net Income 2024
TMO net income (TTM) was $6.00 billion for the quarter ending December 31, 2023, a -13.74% decrease year-over-year.
Thermo Fisher Scientific Inc. (TMO) Cash Flow 2024
TMO recorded a free cash flow (TTM) of $6.93 billion for the quarter ending December 31, 2023, a +0.23% increase year-over-year.
Thermo Fisher Scientific Inc. (TMO) Earnings per Share 2024
TMO earnings per share (TTM) was $15.45 for the quarter ending December 31, 2023, a -12.37% decline year-over-year.
Thermo Fisher Scientific Inc. Stock (TMO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
CASPER MARC N | Chairman & CEO |
Mar 13 '24 |
Option Exercise |
190.59 |
10,000 |
1,905,900 |
133,816 |
CASPER MARC N | Chairman & CEO |
Mar 13 '24 |
Sale |
594.58 |
10,000 |
5,945,759 |
123,816 |
Britt Lisa P. | Sr. VP and Chief HR Officer |
Mar 12 '24 |
Option Exercise |
198.85 |
14,345 |
2,852,545 |
25,768 |
CASPER MARC N | Chairman & CEO |
Mar 12 '24 |
Option Exercise |
190.59 |
10,000 |
1,905,900 |
133,816 |
Britt Lisa P. | Sr. VP and Chief HR Officer |
Mar 12 '24 |
Sale |
598.90 |
14,345 |
8,591,220 |
17,323 |
CASPER MARC N | Chairman & CEO |
Mar 12 '24 |
Sale |
597.98 |
10,000 |
5,979,758 |
123,816 |
CASPER MARC N | Chairman & CEO |
Mar 11 '24 |
Option Exercise |
190.59 |
10,000 |
1,905,900 |
135,816 |
CASPER MARC N | Chairman & CEO |
Mar 11 '24 |
Sale |
595.36 |
10,000 |
5,953,598 |
125,816 |
CASPER MARC N | Chairman & CEO |
Feb 29 '24 |
Option Exercise |
190.59 |
10,000 |
1,905,900 |
135,816 |
CASPER MARC N | Chairman & CEO |
Feb 29 '24 |
Sale |
571.08 |
10,000 |
5,710,818 |
125,816 |
About Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide. Its Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of new drugs and vaccines, as well as diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets. Its Analytical Instruments segment offers instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and research and industrial markets, as well as clinical laboratories. Its Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; blood-test systems; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; products for cancer diagnosis and medical research in histology, cytology, and hematology; human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel products. This segment serves healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. Its Laboratory Products and Services segment offers laboratory refrigerators and freezers, ultralow-temperature freezers and cryopreservation storage tanks, temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis and laboratory equipment; laboratory plastics; laboratory chemicals; research and safety market channel; and pharma services. The company was founded in 1956 and is headquartered in Waltham, Massachusetts.
Cap:
|
Volume (24h):